Newsroom

Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

MENLO PARK, Calif., March 30, 2020 /PRNewswire/ -- Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D., has been published in Current Opinion in Ophthalmology.

read more +
Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MENLO PARK, Calif., March 18, 2020 /PRNewswire/ — Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today...

read more +
Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new...

read more +
Retreatment With A Single TearCare™ Treatment Continues To Provide Relief For Patients With Dry Eye Disease

A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment...

read more +
Sight Sciences Announces Official Launches of TearCare™ and the Enhanced, Next Generation OMNI™ System

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device...

read more +
First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI™ Surgical System for Multiple Micro-Invasive Glaucoma Surgery Procedures

MENLO PARK, Calif. – Sight Sciences today announced enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multi-center study to evaluate the safety and efficacy of the OMNI™...

read more +
Clinical Study Demonstrates Long Term IOP Reduction With The OMNI™ Surgical System Predicate Device (TRAB™360) In Micro-Invasive Glaucoma Surgery

A new, single center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI™ Surgical...

read more +
Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has...

read more +